ABBV Jan 2025 230.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 10:12AM EDT. Market open.
| Previous Close | 0.5000 |
| Open | 0.5000 |
| Bid | 0.2200 |
| Ask | 0.7500 |
| Strike | 230.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 0.5000 - 0.5000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 108 |
ZacksPharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.
PR NewswirePhase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
AbbVie (NYSE: ABBV) today announced positive top-line results from SELECT-GCA, a Phase 3, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (RINVOQ®; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week 12 through week 52 in adults with giant cell arteritis (GCA). In this study, 46 percent of patients receiving upadacitinib 15 mg in combination with a 26-week steroid taper regime
ZacksAbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know
AbbVie (ABBV) closed at $164.25 in the latest trading session, marking a +1.05% move from the prior day.
© 2024 Yahoo. All rights reserved.